Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Decrease in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totaling 2,168,608 shares, a decrease of 29.8% from the December 15th total of 3,088,368 shares. Based on an average trading volume of 269,707 shares, the days-to-cover ratio is presently 8.0 days. Approximately 4.5% of the shares of the stock are short sold. Approximately 4.5% of the shares of the stock are short sold. Based on an average trading volume of 269,707 shares, the days-to-cover ratio is presently 8.0 days.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Squarepoint Ops LLC grew its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 328,794 shares of the company’s stock after buying an additional 93,338 shares during the period. Squarepoint Ops LLC owned approximately 0.63% of Xilio Therapeutics worth $277,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 54.29% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $2.00.

Xilio Therapeutics Price Performance

XLO opened at $0.64 on Friday. The company has a market cap of $33.61 million, a price-to-earnings ratio of -0.98 and a beta of -0.06. The firm has a 50 day simple moving average of $0.70 and a 200 day simple moving average of $0.73. Xilio Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last issued its earnings results on Thursday, November 13th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $19.07 million during the quarter, compared to analysts’ expectations of $18.64 million. Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%. As a group, analysts expect that Xilio Therapeutics will post -1.14 EPS for the current year.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.